<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584908</url>
  </required_header>
  <id_info>
    <org_study_id>UofA - AdVEnTR</org_study_id>
    <nct_id>NCT01584908</nct_id>
  </id_info>
  <brief_title>Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients</brief_title>
  <official_title>Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients(AdVEnTR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza is an important public health problem. Organ transplant patients are particularly&#xD;
      susceptible to severe disease. Also, they shed higher quantities of virus for longer&#xD;
      durations, leading to greater contagious potential, thereby potentially serving as nodes of&#xD;
      spread in the community. Therefore, improved strategies to prevent influenza in this&#xD;
      population is an important public health concern. Standard vaccination is poorly immunogenic&#xD;
      post-transplant and new vaccine strategies are needed. Adjuvanted vaccines contain molecules&#xD;
      that create a strong local inflammatory response and they attract immune cells to the site of&#xD;
      injection, increasing the immunogenicity of the vaccine antigen. Recently seasonal influenza&#xD;
      vaccines containing adjuvants have become available in Canada but have only limited&#xD;
      information in transplant patients. This randomized trial is designed to assess the&#xD;
      immunogenicity of an adjuvanted vaccination strategy compared to a standard vaccine for&#xD;
      seasonal influenza in a cohort of adult organ transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">68</enrollment>
  <condition>Influenza</condition>
  <eligibility>
    <study_pop>
      <textblock>
        adult kidney tranplant recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult kidney transplant recipients Greater than 3 months post-transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Has already received influenza vaccination for 2012-2013 season Egg allergy Previous&#xD;
        life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome) Ongoing&#xD;
        therapy for rejection Febrile illness in the past two weeks Unable to provide informed&#xD;
        consent Unable to comply with study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepali Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>December 31, 2014</last_update_submitted>
  <last_update_submitted_qc>December 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant recipients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

